{"ctNumber":"2024-518482-99-01","ctStatus":"Authorised","startDateEU":"2020-11-16","decisionDate":"2025-01-15T20:23:56.001","publishDate":"2025-07-09T03:35:38.997601662","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":63963,"rowSubjectCount":0,"products":[{"id":260628,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11222925","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD3117103","marketingAuthNumber":"EU/1/12/797/002","prodAuthStatus":2,"prodName":"Eylea 40 mg/mL solution for injection in a vial","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"AFLIBERCEPT","euSubstNumber":"SUB26987","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/002392","nameOrg":"BAYER AG","productSubstances":[{"productPk":"11222925","substancePk":"354554","nameOrg":"BAYER AG","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"AFLIBERCEPT","substanceEvCode":"SUB26987","synonyms":["BAY 86-5321","ABP 938","AVE0005","BAY86-5321","VEGF TRAP","BAY 86-5319"]}],"atcCode":"S01LA05","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD3117103","devices":[],"characteristics":[],"routes":["INJECTION"],"allSubstancesChemicals":false,"productName":"Eylea 40 mg/mL solution for injection in a vial","jsonActiveSubstanceNames":"aflibercept","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":260627,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11344859","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE","euMpNumber":"PRD2393542","marketingAuthNumber":"EU/1/06/374/003","prodAuthStatus":2,"prodName":"Lucentis 10 mg/ml solution for injection in pre-filled syringe","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"RANIBIZUMAB","euSubstNumber":"SUB22314","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/000715","nameOrg":"NOVARTIS EUROPHARM LIMITED","productSubstances":[{"productPk":"11344859","substancePk":"376811","nameOrg":"NOVARTIS EUROPHARM LIMITED","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"RANIBIZUMAB","substanceEvCode":"SUB22314"}],"atcCode":"S01LA04","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"0.5","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"0.5","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD2393542","devices":[],"characteristics":[],"routes":["INJECTION"],"allSubstancesChemicals":false,"productName":"Lucentis 10 mg/ml solution for injection in pre-filled syringe","jsonActiveSubstanceNames":"ranibizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":260629,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11341079","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE","euMpNumber":"PRD7894494","marketingAuthNumber":"EU/1/19/1417/001","prodAuthStatus":2,"prodName":"Beovu 120 mg/ml solution for injection in pre-filled syringe","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"BROLUCIZUMAB","euSubstNumber":"SUB180753","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/004913","nameOrg":"NOVARTIS EUROPHARM LIMITED","productSubstances":[{"productPk":"11341079","substancePk":"364159","nameOrg":"NOVARTIS EUROPHARM LIMITED","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"BROLUCIZUMAB","substanceEvCode":"SUB180753"}],"atcCode":"S01LA06","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"6","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"6","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD7894494","devices":[],"characteristics":[],"routes":["INJECTION"],"allSubstancesChemicals":false,"productName":"Beovu 120 mg/ml solution for injection in pre-filled syringe","jsonActiveSubstanceNames":"brolucizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Personalized treatment aided by automated analysis of fluid in\nactive neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study","fullTitleTranslations":[{"id":4523071,"uuid":"1b00ab9f-d4e4-4cab-8683-47f75f56313a","attributeTranslation":"Personalisiertes Behandlungsschema unter Zuhilfenahme automatischer Analyse von Flüssigkeitsansammlungen in der Makula bei aktiver altersbedingter Makuladegeneration (AMD); eine prospektive, multizentrische, randomisierte Studie","language":27,"languageDescription":"German (Austria)"}],"publicTitle":"Treatment of neovascular AMD: Artificial intelligence in real-world setting","publicTitleTranslations":[],"secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"6","trialCategory":"3","justificationForTrialCategory":"Phase IV clincial trial","trialCategoryId":55829},"medicalCondition":{"partIMedicalConditions":[{"id":64185,"medicalCondition":"neovasclar AMD","medicalConditionTranslations":[],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"5","trialScopeId":184842}],"mainObjective":"The purpose of this study is to implement quantitative assessment tools for the\ntreatment of active neovascular AMD patients in a real-world setting in order to provide\nadvantages for both patients (treatment burden) and healthcare system (scheduling\nvisits/treatments).","mainObjectiveTranslations":[],"secondaryObjectives":[]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":404022,"number":1,"principalInclusionCriteria":"- Adults ≥ 50 years","principalInclusionCriteriaTranslations":[]},{"id":404023,"number":2,"principalInclusionCriteria":"- Active neovascular AMD (classic, occult choroidal neovascularization (CNV), RAP lesion or PCV lesion) assessed by OCT, OCTA, FA","principalInclusionCriteriaTranslations":[]},{"id":404024,"number":3,"principalInclusionCriteria":"- Patients who have a BCVA score better or equal 0.1 (20/200) in the study eye using ETDRS","principalInclusionCriteriaTranslations":[]},{"id":404025,"number":4,"principalInclusionCriteria":"- No significant fibrosis or geographic atrophy (GA) involving the fovea","principalInclusionCriteriaTranslations":[]},{"id":404026,"number":5,"principalInclusionCriteria":"- Willingness and ability to comply with study visits and study procedures","principalInclusionCriteriaTranslations":[]},{"id":404027,"number":6,"principalInclusionCriteria":"- Signed informed consent form","principalInclusionCriteriaTranslations":[]}],"principalExclusionCriteria":[{"id":696761,"number":1,"principalExclusionCriteria":"- Hypersensitivity to Fluoresceine, Ranibizumab, Aflibercept, Brolucizumab or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose)","principalExclusionCriteriaTranslations":[]},{"id":696762,"number":10,"principalExclusionCriteria":"- Active or suspected ocular or periocular infection in the study eye","principalExclusionCriteriaTranslations":[]},{"id":696763,"number":11,"principalExclusionCriteria":"- Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye","principalExclusionCriteriaTranslations":[]},{"id":696764,"number":12,"principalExclusionCriteria":"- Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment","principalExclusionCriteriaTranslations":[]},{"id":696765,"number":13,"principalExclusionCriteria":"- Evidence of current infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye","principalExclusionCriteriaTranslations":[]},{"id":696766,"number":14,"principalExclusionCriteria":"- Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery) during the study period","principalExclusionCriteriaTranslations":[]},{"id":696767,"number":15,"principalExclusionCriteria":"- Presence of corneal decompensation, haze or scaring with an impact on BCVA","principalExclusionCriteriaTranslations":[]},{"id":696768,"number":2,"principalExclusionCriteria":"- Any surgical treatment of the eye within 3 months prior to baseline in the study eye","principalExclusionCriteriaTranslations":[]},{"id":696769,"number":3,"principalExclusionCriteria":"- History of pseudophakic cystoid macular edema (Irvine Gass Syndrome)","principalExclusionCriteriaTranslations":[]},{"id":696770,"number":4,"principalExclusionCriteria":"- History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 0, or a history of post-operative complications within the last 12 months preceding Visit 0 in the study eye (uveitis, cyclitis etc.)","principalExclusionCriteriaTranslations":[]},{"id":696771,"number":5,"principalExclusionCriteria":"- History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio >0,9","principalExclusionCriteriaTranslations":[]},{"id":696772,"number":6,"principalExclusionCriteria":"- Aphakia in the study eye","principalExclusionCriteriaTranslations":[]},{"id":696773,"number":7,"principalExclusionCriteria":"- Presence of a retinal pigment epithelial tear involving the macula in the study eye","principalExclusionCriteriaTranslations":[]},{"id":696774,"number":8,"principalExclusionCriteria":"- Any concurrent intraocular condition in the study eye (e.g. advanced cataract or diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the twelve-month study period to prevent or treat visual loss that might result from that condition","principalExclusionCriteriaTranslations":[]},{"id":696775,"number":9,"principalExclusionCriteria":"- Active intraocular inflammation (grade trace or above) in the study eye","principalExclusionCriteriaTranslations":[]}]},"endPoint":{"primaryEndPoints":[{"id":469474,"number":1,"endPoint":"- Number of anti-VEGF injections","isPrimary":true,"endPointTranslations":[]}],"secondaryEndPoints":[{"id":469475,"number":1,"endPoint":"- Best-corrected visual acuity (BCVA) assessed by ETDRS Score","isPrimary":false,"endPointTranslations":[]},{"id":469476,"number":2,"endPoint":"- Anatomic changes in the macula assessed with OCT (central retinal thickness, fluid volumes in nl, additional morphologic changes)","isPrimary":false,"endPointTranslations":[]},{"id":469477,"number":3,"endPoint":"- Formation of geographic-like macular atrophy assessed by fundus photography with special filters","isPrimary":false,"endPointTranslations":[]},{"id":469478,"number":4,"endPoint":"- Formation of retinal tears assessed by OCT","isPrimary":false,"endPointTranslations":[]},{"id":469479,"number":5,"endPoint":"- Chorioretinal perfusion changes (OCTA)","isPrimary":false,"endPointTranslations":[]},{"id":469480,"number":6,"endPoint":"- Perfusion of the neovascular lesion (OCTA, FA)","isPrimary":false,"endPointTranslations":[]},{"id":469481,"number":7,"endPoint":"- Changes in macular sensitivity (MP)","isPrimary":false,"endPointTranslations":[]},{"id":469482,"number":8,"endPoint":"- Assessment of fibrosis formation and deterioration of the retinal pigment epithelium (PS-OCT)","isPrimary":false,"endPointTranslations":[]},{"id":469483,"number":9,"endPoint":"- Quality-of-life assessed by questionnaire","isPrimary":false,"endPointTranslations":[]}]},"trialDuration":{"estimatedEndDate":"2025-08-28","estimatedRecruitmentStartDate":"2020-04-14"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":172838,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":172837,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"2","planDescription":"All data remains within the Medical university of Vienna."}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[{"id":15574,"ctNumber":"2024-518482-99-00","sponsorName":"Medical University Of Vienna","fullTitle":"Personalized treatment aided by automated analysis of fluid in\nactive neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":19648,"hasDocument":false,"associatedCtDocs":[]}],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-01-10","conclusionDate":"2025-01-10","therapeuticAreas":[{"code":"11","name":"Diseases [C] - Eye Diseases [C11]"}],"medicalConditions":[{"id":64185,"medicalCondition":"neovasclar AMD","isConditionRareDisease":false}],"sponsors":[{"id":68220,"primary":true,"publicContacts":[{"id":203493,"type":"Public","functionalName":"Department of Ophthalmology and Optometry","functionalEmailAddress":"Georg.Ehrlich@meduniwien.ac.at","telephone":"+434040048471","organisation":{"id":642027,"type":"Educational Institution","typeCode":"1","name":"Medical University Of Vienna","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100006190","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":203494,"type":"Scientific","functionalName":"Department of Ophthalmology and Optometry","functionalEmailAddress":"Georg.Ehrlich@meduniwien.ac.at","telephone":"+434040048471","organisation":{"id":642027,"type":"Educational Institution","typeCode":"1","name":"Medical University Of Vienna","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100006190","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":642027,"type":"Educational Institution","typeCode":"1","name":"Medical University Of Vienna","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100006190","organisationLocationStatus":"Active"},"addresses":[{"id":606669,"organisation":{"id":642027,"type":"Educational Institution","typeCode":"1","name":"Medical University Of Vienna","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100006190","organisationLocationStatus":"Active"},"address":{"addressId":655272,"oneLine":"Spitalgasse 23, Alsergrund","addressLine1":"Spitalgasse 23","addressLine2":"Alsergrund","addressLine3":"","addressLine4":"","city":"Vienna","postcode":"1090","country":2000,"countryName":"Austria"},"isBusinessKeyValidated":true,"businessKey":"ORG-100006190"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"3","trialCategoryJustificationComment":"Phase IV clincial trial","partOneTherapeuticAreas":[{"id":693284,"therapeuticArea":{"code":"11","name":"Diseases [C] - Eye Diseases [C11]"}}],"productRoleGroupInfos":[{"id":200918,"comments":"Beovu 120 mg/ml solution for injection in pre-filled syringe","productRoleCode":"1","productRoleName":"Test","products":[{"id":260629,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11341079","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE","euMpNumber":"PRD7894494","marketingAuthNumber":"EU/1/19/1417/001","prodAuthStatus":2,"prodName":"Beovu 120 mg/ml solution for injection in pre-filled syringe","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"BROLUCIZUMAB","euSubstNumber":"SUB180753","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/004913","nameOrg":"NOVARTIS EUROPHARM LIMITED","productSubstances":[{"productPk":"11341079","substancePk":"364159","nameOrg":"NOVARTIS EUROPHARM LIMITED","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"BROLUCIZUMAB","substanceEvCode":"SUB180753"}],"atcCode":"S01LA06","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"6","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"6","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD7894494","devices":[],"characteristics":[],"routes":["INJECTION"],"allSubstancesChemicals":false,"productName":"Beovu 120 mg/ml solution for injection in pre-filled syringe","jsonActiveSubstanceNames":"brolucizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]},{"id":200916,"comments":"Lucentis 10 mg/ml solution for injection in pre-filled syringe","productRoleCode":"1","productRoleName":"Test","products":[{"id":260627,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11344859","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE","euMpNumber":"PRD2393542","marketingAuthNumber":"EU/1/06/374/003","prodAuthStatus":2,"prodName":"Lucentis 10 mg/ml solution for injection in pre-filled syringe","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"RANIBIZUMAB","euSubstNumber":"SUB22314","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/000715","nameOrg":"NOVARTIS EUROPHARM LIMITED","productSubstances":[{"productPk":"11344859","substancePk":"376811","nameOrg":"NOVARTIS EUROPHARM LIMITED","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"RANIBIZUMAB","substanceEvCode":"SUB22314"}],"atcCode":"S01LA04","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"0.5","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"0.5","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD2393542","devices":[],"characteristics":[],"routes":["INJECTION"],"allSubstancesChemicals":false,"productName":"Lucentis 10 mg/ml solution for injection in pre-filled syringe","jsonActiveSubstanceNames":"ranibizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]},{"id":200917,"comments":"Eylea 40 mg/mL solution for injection in a vial","productRoleCode":"1","productRoleName":"Test","products":[{"id":260628,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11222925","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD3117103","marketingAuthNumber":"EU/1/12/797/002","prodAuthStatus":2,"prodName":"Eylea 40 mg/mL solution for injection in a vial","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"AFLIBERCEPT","euSubstNumber":"SUB26987","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/002392","nameOrg":"BAYER AG","productSubstances":[{"productPk":"11222925","substancePk":"354554","nameOrg":"BAYER AG","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"AFLIBERCEPT","substanceEvCode":"SUB26987","synonyms":["BAY 86-5321","ABP 938","AVE0005","BAY86-5321","VEGF TRAP","BAY 86-5319"]}],"atcCode":"S01LA05","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD3117103","devices":[],"characteristics":[],"routes":["INJECTION"],"allSubstancesChemicals":false,"productName":"Eylea 40 mg/mL solution for injection in a vial","jsonActiveSubstanceNames":"aflibercept","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":158093,"mscId":42078,"mscInfo":{"id":42078,"clinicalTrialId":20757,"countryOrganisationId":2000,"reportingStatusCode":"Authorised","fromDate":"2024-11-19","toDate":"2024-11-19","isProposedRms":true,"countryName":"Austria","organisationInfo":{},"firstDecisionDate":"2025-01-15","trialStatus":"Authorised","trialPeriod":[{"id":60357,"trialStartDate":"2020-11-16","fromDate":"2025-07-08"},{"id":60358,"trialStartDate":"2020-11-16","fromDate":"2025-07-08"}],"trialRecruitmentPeriod":[{"id":81671,"recruitmentStartDate":"2021-02-18","fromDate":"2025-07-08"},{"id":81672,"recruitmentStartDate":"2021-02-18","fromDate":"2025-07-08"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":89573,"trialStartDate":"2020-11-16","fromDate":"2025-07-08"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2021-02-18"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":59979,"mscId":42078,"trialStatus":"Under evaluation","trialStatusDate":"2024-11-06T10:43:06.225"},{"id":73880,"mscId":42078,"trialStatus":"Authorised","trialStatusDate":"2025-01-15T20:23:55.63"}],"applicationTypeMsc":"1","mscName":"Austria","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-12-10","decision":"authorized","decisionDate":"2025-01-15"},"decisionDate":"2025-01-15","recruitmentSubjectCount":290,"trialSites":[{"id":1026216,"organisationAddressInfo":{"id":606689,"organisation":{"id":642047,"type":"Educational Institution","typeCode":"1","name":"Medical University Of Vienna","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100006190","organisationLocationStatus":"Active"},"address":{"addressId":655294,"oneLine":"Waehringer Guertel 18-20, Alsergrund","addressLine1":"Waehringer Guertel 18-20","addressLine2":"Alsergrund","addressLine3":"","addressLine4":"","city":"Vienna","postcode":"1090","country":2000,"countryName":"Austria"},"phone":"+4314040079375","email":"stefan.sacu@meduniwien.ac.at","isBusinessKeyValidated":true,"businessKey":"ORG-100006190"},"personInfo":{"id":1146371,"firstName":"Stefan","lastName":"Sacu","telephone":"+4314040079375","email":"stefan.sacu@meduniwien.ac.at","title":"2"},"departmentName":"Department of Ophthalmology and Optometry"},{"id":1026217,"organisationAddressInfo":{"id":644942,"organisation":{"id":682914,"type":"Health care","typeCode":"2","name":"Landesklinikum Horn","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000011973","organisationLocationStatus":"Active"},"address":{"addressId":699406,"oneLine":"Landeshauptplatz 1 Haus 13","addressLine1":"Landeshauptplatz 1 Haus 13","addressLine2":"","addressLine3":"","addressLine4":"","city":"St. Pölten","postcode":"3109","country":2000,"countryName":"Austria"},"phone":"+43298290040","email":"Stefan.Heiligenbrunner@horn.lknoe.at","isBusinessKeyValidated":false,"businessKey":"ORL-000011973"},"personInfo":{"id":1146372,"firstName":"Stefan","lastName":"Heiligenbrunner","telephone":"+43298290040","email":"Stefan.Heiligenbrunner@horn.lknoe.at"},"departmentName":"Department of Ophthalmology and Optometry"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":40062,"type":"INITIAL","status":"Authorised","ctNumber":"2024-518482-99-01","trialStatus":"Authorised","submissionDate":"2024-11-06","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-01-10"},"partIIInfo":[{"id":158093,"mscId":42078,"mscInfo":{"id":42078,"mscName":"Austria","countryOrganisationId":2000,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-12-10","decision":"authorized","decisionDate":"2025-01-15","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-01-15"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-01-15","ctMSCsByApplication":[{"id":42078,"mscName":"Austria","reportingStatusCode":"Authorised"}],"businessKey":"IN-1","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":53347,"applicationId":40062,"mscId":42078,"mscName":"Austria","decisionDate":"2025-01-15T20:23:56.001","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":158093,"part1Id":63963,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"345348cd-9940-440b-b76e-6beaa45a82b1","productRoleGroupId":200918},{"documentUuid":"777edee1-f9df-401a-aa4a-06d63fe17e27","productRoleGroupId":200916},{"documentUuid":"0afb239a-fb7f-4f7b-a6c5-a43a2f5bf349","productRoleGroupId":200917}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Austria","mscId":42078,"firstDecisionDate":"2025-01-15T20:23:56.001","lastDecisionDate":"2025-01-15T20:23:56.001","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2019-003133-42"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":42078,"mscName":"Austria","events":[{"notificationType":"START_OF_TRIAL","date":"2020-11-16"},{"notificationType":"START_OF_RECRUITMENT","date":"2021-02-18"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol 2024-518482-99-00","uuid":"2e04f243-5cd8-420e-a6b9-ff5e3d83e6ad","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":63963,"manualVersion":"4.3","systemVersion":"1"},{"title":"D1_Protocol 2024-518482-99-00_redacted","uuid":"f38d5a6a-6c54-46d5-a81b-0f0e6747015c","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":63963,"manualVersion":"4.3","systemVersion":"1"},{"title":"E2_SmPC_Beovu 120 mg_ml solution for injection in pre-filled syringe","uuid":"345348cd-9940-440b-b76e-6beaa45a82b1","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":200918,"manualVersion":"1","systemVersion":"1"},{"title":"E2_SmPC_Lucentis 10 mg_ml solution for injection in pre-filled syringe","uuid":"777edee1-f9df-401a-aa4a-06d63fe17e27","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":200916,"manualVersion":"1","systemVersion":"1"},{"title":"E2_SmPC_Eylea 40 mg_ml solution for injection in pre-filled syringe","uuid":"0afb239a-fb7f-4f7b-a6c5-a43a2f5bf349","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":200917,"manualVersion":"1","systemVersion":"1"},{"title":"PlaceholderDocument","uuid":"aebe4e03-ad35-46ac-964f-cd42e9cd74ae","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":158093,"manualVersion":"1","systemVersion":"1"},{"title":"L1_ICF description adults","uuid":"6ba412d4-2c5f-43f7-8fe7-ddb79b91f585","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":158093,"manualVersion":"4.5","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}